News and Trends 17 Nov 2017 British Biotech Gets Ready to Launch a New Antibiotic Drug to Fight Resistance Update (17/11/2017): Motif Bio will raise up to $20M (€17M) in the form of a loan from US firm Hercules Capital. The funds will be used to fund the pre-commercialization stage of iclaprim, a new antibiotic that is expected to be launched in the US in 2019. Originally published on 04/10/2017 Iclaprim is a new antibiotic […] November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 German Cancer Sensor Raises the Alarm and Puts the Fire Out No need to call the fire brigade! The University of Dresden’s cancer sensor spots a mutation to p53, the most important cancer gene, and kills the cell. Researchers at the University of Dresden, Germany, have developed a molecular sensor that detects a mutation in tumor protein p53 – implicated in 50% of cancers – and kills […] November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […] November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 Anti-Parasite Drug May Help to Treat Prostate Cancer, Say Norwegian Scientists Researchers in Norway have found that a drug used to kill parasites like tapeworms can slow the growth of prostate and colon cancer cells. A group from the University of Bergen have been testing hundreds of drugs to see how they affect cancer cells. They have now found a drug taken to treat intestinal parasites, Giardia and […] November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 German Scientists Test Out New HIV Vaccine Combinations in Animals Scientists from the German Primate Center have investigated the impact of the delivery route and order of components on the success of an HIV vaccine. With more than 36 million people infected with the human immunodeficiency virus (HIV) and a further 2.4 million infected each year, something needs to be done. Researchers from the German […] November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 16 Nov 2017 Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates […] November 16, 2017 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 New British Biotech Receives £3M to Develop Small Molecules that Fight Cancer NeoPhore, has received investment from Sixth Element Capital to develop small molecules that stimulate the immune system against cancer. Sixth Element Capital has invested £3M (€3.3M) in NeoPhore, a new spin-out from PhoreMost – a drug discovery company based in Cambridge, UK. NeoPhore has been set up to explore small molecules that could be used to stimulate […] November 15, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another one being developed by BioNTech. Moderna Therapeutics has announced the start of a Phase 1 study with mRNA-4157, a therapy consisting of a cancer vaccine that is tailored to each patient’s individual tumor. In order to make this personalized treatment, […] November 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Swiss Biotech Rakes in Biggest Fundraising of 2017 to Regenerate Heart Valves Xeltis has raised a €45M Series C to boost the development of its pioneering medical device, RestoreX, which helps to replace damaged heart valves. Xeltis, based in Zurich, Switzerland, is a clinical-stage medical device company developing heart valves and blood vessels to allow the body to naturally restore heart valve function. The biotech has achieved a €45M […] November 15, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […] November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 Spanish Scientists’ Discovery Could be the End of Antibiotic-Resistant Superbugs Superbugs might not be so super for long, as Spanish scientists have found a way to block the mechanisms by which they develop antibiotic resistance. Researchers from the Spanish National Research Council (CSIC) have made a big breakthrough in the battle against antibiotic-resistant bacteria. In a study published in Cell, they designed molecules that block the cellular […] November 15, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 15 Nov 2017 Therapeutic Nanoparticle Companies Are Rare: Meet the CEO of One of Them In our last BIO Europe interview, I caught up with CEO Timm Jessen of Topas Therapeutics to hear about the company’s nanoparticles. Founded in 2013 as a spinout from Evotec, Topas Therapeutics is developing nanoparticles for a whole range of diseases and with CEO Timm Jessen at the helm. He told me the story of […] November 15, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email